Affimed N.V announced the appointment of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020. Dr. Schottelius will lead Affimed’s discovery, translational innovation and platform engineering teams. In addition, Dr. Schottelius will lead the company’s preclinical development activities, initiatives to generate additional innate cell engagers based on its proprietary fit-for-purpose ROCK® (Redirected Optimized Cell Killing) platform and efforts to strengthen Affimed’s intellectual property. Dr. Schottelius will also take a lead role in furthering Affimed’s ongoing Genentech partnership and other key collaborations. Most recently, Dr. Schottelius was Executive Vice President and Head of Research & Development at Kymab Group Limited, where he was responsible for expanding the therapeutic antibody portfolio.